Compare AbbVie Inc (ABBV) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Booz Allen Hamilton Holding Corporation — how do they compare? AbbVie Inc trades at $253.77 (market cap $449.91B), while Booz Allen Hamilton Holding Corporation trades at $62.61 (market cap $7.59B). The key difference: AbbVie Inc is far larger — about 59.3× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| ABBV | BAH | |
|---|---|---|
Market Cap | $449.91B | $7.59B |
Sector | Health | Industrials |
52-Week High | $261.07 | $115.95 |
52-Week Low | $184.85 | $59.71 |
Enterprise Value | $513.38B | $10.99B |
Dividend Yield | 2.72% | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Booz Allen Hamilton (BAH) trades at $63.31, up 1.38% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $12.0B in 2025 and impressive profitability metrics including 80.17% ROE. Recent developments include strategic AI partnerships with OpenAI and acquisitions to strengthen defense technology capabilities, though the stock faces near-term pressure from civil business weakness.
BAH presents a compelling value opportunity with attractive valuation multiples (P/E 9.03, P/S 0.68) and analyst consensus target of $87.25 representing 38% upside. However, investors face risks from FY27 transition expectations, civil segment pressures, and technical resistance near $64-65 levels. The company's government-focused model provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
